基于Hsp90-Tau相互作用的合成护卫剂抑制了Tau的聚合,并挽救了生理上的Tau-Microtubule相互作用
Davide Di Lorenzo1,2,3, Nicolo Bisi1,4, Julia Kaffy1
1Université Paris-Saclay, CNRS, BioCIS, Bat. Henri Moissan, 17 av. des Sciences, 91400, Orsay, France.
Nature communications
|October 1, 2025
概括
一种新型的,β-Hsp90,模仿伴侣Hsp90,以抑制阿尔茨海默病 (AD) 模型中的Tau聚合. 这种可以恢复微管的功能,还可以减少粉样β聚合,从而提供双重治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 陶蛋白聚合成细胞内神经纤维状结是阿尔茨海默病 (AD) 的标志.
- 像Hsp90这样的陪伴蛋白通常可以防止蛋白质错误折叠和聚合,但随着年龄的增长,它们的有效性会下降.
- 对于Hsp90在防止Tau聚合中的确切作用尚不完全理解.
研究的目的:
- 设计和评估一种新型模仿药,β-Hsp90,它模仿Hsp90的功能以抑制Tau聚合.
- 在AD的细胞和体外模型中研究β-Hsp90的治疗潜力.
- 评估β-Hsp90作为和粉样β (Aβ) 聚合的双抑制剂的疗效.
主要方法:
- 设计β-Hsp90,一个由Hsp90/Tau相互作用序列启发的β-hairpin型模拟剂.
- 在体外和细胞测试以评估β-Hsp90.0.的Tau聚合的抑制.
- 对β-Hsp90对Tau微管相互作用和Aβ1-42聚合的影响的评估.
主要成果:
- 在体外和细胞模型中,β-Hsp90有效抑制tau聚合.
- 类药物恢复了Tau与微管的生理相互作用.
- 与单个序相比,β-Hsp90显示出更高的疗效,并显示出对Aβ1-42聚合的双重抑制活性.
结论:
- β-Hsp90通过模仿陪伴者功能,代表了阿尔茨海默病的有希望的治疗策略.
- 这种方法为粉样蛋白疾病提供了一个新的双重向药物候选者.
- 模仿生理伴侣的合成类药物的设计有可能用于治疗神经退行性疾病.
相关概念视频
Molecular Chaperones and Protein Folding
19.6K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
19.6K
Molecular Chaperones and Protein Folding
14.8K
14.8K
Bacterial Protein Maturation
468
Bacterial protein maturation is a tightly regulated process that ensures newly synthesized polypeptides achieve correct functional conformations. This maturation involves a series of modifications, folding events, and quality control steps, often assisted by specialized chaperone proteins.N-Terminal ModificationsThe maturation of bacterial polypeptides begins cotranslationally as the polypeptide exits the ribosome. The first amino acid, N-formylmethionine (fMet), is typically modified at the...
468
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Microtubule Associated Proteins (MAPs)
5.8K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
5.8K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K


